Evidence map›Paper›PMID 39328022›Full record

Trial reportClinical pharmacology and therapeutics2025

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.

Chi-Chung Li, Brendan Bender, Justin Wilkins, Feifei Li, David C Turner, Bei Wang, Rong Deng, Shweta Vadhavkar, Zao Li, Antonia Kwan and 8 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Chi-Chung LiGenentech, Inc., South San Francisco, California, USA.ORCID 0000-0002-9590-3450
Brendan BenderGenentech, Inc., South San Francisco, California, USA.ORCID 0000-0002-1093-0661
Justin WilkinsOccams Coöperatie UA, Amstelveen, The Netherlands.
Feifei LiGenentech, Inc., South San Francisco, California, USA.ORCID 0009-0003-7817-0819
David C TurnerGenentech, Inc., South San Francisco, California, USA.
Bei WangGenentech, Inc., South San Francisco, California, USA.ORCID 0000-0002-9530-0385
Rong DengGenentech, Inc., South San Francisco, California, USA.ORCID 0000-0003-2005-7517
Shweta VadhavkarGenentech, Inc., South San Francisco, California, USA.ORCID 0009-0009-1339-2748
Zao LiGenentech, Inc., South San Francisco, California, USA.
Antonia KwanGenentech, Inc., South San Francisco, California, USA.
Huang HuangHoffmann-La Roche Ltd, Mississauga, Ontario, Canada.
Kun PengGenentech, Inc., South San Francisco, California, USA.
Elicia PenuelGenentech, Inc., South San Francisco, California, USA.
Ling-Yuh HuwGenentech, Inc., South San Francisco, California, USA.
Pascal ChanuGenentech, Inc./F, Hoffmann-La Roche Ltd, Lyon, France.ORCID 0000-0001-9011-5431
Chunze LiGenentech, Inc., South San Francisco, California, USA.
Shen YinGenentech, Inc., South San Francisco, California, USA.ORCID 0009-0004-4889-5314
Michael C WeiGenentech, Inc., South San Francisco, California, USA.ORCID 0009-0005-3805-7189

Funding

Roche
6 · The paper itself

Abstract

Mosunetuzumab, a T-cell engaging bispecific antibody targeting CD20xCD3, is approved for treating relapsed/refractory follicular lymphoma. This research supports the approved intravenous clinical dose regimen, summarizing the exposure-response relationships for clinical safety and efficacy. A population pharmacokinetic model and E

Indexed as

Antibodies, BispecificAntineoplastic Agents, ImmunologicalLymphoma, FollicularLymphoma, Non-HodgkinAdultAgedAged, 80 and overArea Under CurveDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedModels, BiologicalTreatment OutcomeAntibodies, BispecificAntineoplastic Agents, Immunological

Identifiers

PMID39328022
PMCPMC11739751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.